Document detail
ID

doi:10.1186/s13256-023-03902-4...

Author
Yoneto, Toshihiko Hasumi, Kenichiro Takahashi, Nobukazu Seki, Nastuki Takeda, Yasutaka Yoshimoto, Takayuki
Langue
en
Editor

BioMed Central

Category

Medicine & Public Health

Year

2023

listing date

5/10/2023

Keywords
breast cancer cdk4/6 inhibitors complete remission immune systems immunosenescent t cell recurrence cells recurrence immune cancer breast
Metrics

Abstract

Background The prognosis for recurrence cases of hormone receptor-positive HER2-negative breast cancer remains poor, and treatment strategies that emphasize quality of life have often been chosen, with few physicians aiming for a cure.

Our objective is to assess the validity of such current treatment strategies.

Case presentation A 74-year-old Asian woman with multiple lung and liver metastases after local recurrence of breast cancer was treated with two different cyclin-dependent kinases 4/6 inhibitors sequentially in combination with endocrine therapy.

Flow cytometric analysis of the patient’s peripheral blood mononuclear cells was also performed to evaluate the host’s immune status.

Complete remission was achieved without cytotoxic agents and the patient remains disease free to this day, 6 years after the initial relapse.

Additionally, no increase in the population of the immunosenescent T cells with a phenotype of CD8^+CD28^− was observed in the patient’s peripheral blood mononuclear cells, suggesting that the immune system was well maintained.

Conclusions We present this case study to develop new treatment strategies for recurrent breast cancer that is not only bound to misinterpretations of the Hortobagyi algorithm, but also aim for a cure with noncytotoxic agents to maintain the host’s immune system and early detection of recurrence.

Yoneto, Toshihiko,Hasumi, Kenichiro,Takahashi, Nobukazu,Seki, Nastuki,Takeda, Yasutaka,Yoshimoto, Takayuki, 2023, Long-lasting complete remission in a patient with systemic metastases of recurrent breast cancer treated with cyclin-dependent kinases 4/6 inhibitors: a case report, BioMed Central

Document

Open

Share

Source

Articles recommended by ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw